Analysts Set NeuroPace, Inc. (NASDAQ:NPCE) PT at $18.67

Shares of NeuroPace, Inc. (NASDAQ:NPCE) have earned an average rating of “Moderate Buy” from the eight analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $18.6667.

A number of research firms have commented on NPCE. UBS Group reissued a “buy” rating on shares of NeuroPace in a research note on Wednesday, January 14th. Wall Street Zen raised shares of NeuroPace from a “hold” rating to a “buy” rating in a report on Saturday. Cantor Fitzgerald upgraded shares of NeuroPace to a “strong-buy” rating in a research report on Wednesday, March 4th. HC Wainwright increased their target price on NeuroPace from $18.00 to $19.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Finally, JPMorgan Chase & Co. lifted their price target on NeuroPace from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th.

NeuroPace Stock Performance

NASDAQ:NPCE opened at $14.05 on Friday. The stock has a market cap of $473.06 million, a P/E ratio of -21.29 and a beta of 1.86. The company has a quick ratio of 4.33, a current ratio of 5.28 and a debt-to-equity ratio of 3.09. The business’s 50-day moving average price is $15.51 and its two-hundred day moving average price is $13.41. NeuroPace has a twelve month low of $7.56 and a twelve month high of $18.98.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.06. The company had revenue of $26.59 million during the quarter, compared to analyst estimates of $24.79 million. NeuroPace had a negative return on equity of 105.67% and a negative net margin of 21.47%. As a group, equities analysts predict that NeuroPace will post -1 EPS for the current fiscal year.

Institutional Trading of NeuroPace

Hedge funds have recently bought and sold shares of the company. Kotler Kevin bought a new position in NeuroPace during the fourth quarter valued at approximately $9,750,000. Divisadero Street Capital Management LP lifted its holdings in shares of NeuroPace by 529.2% in the 2nd quarter. Divisadero Street Capital Management LP now owns 242,120 shares of the company’s stock worth $2,697,000 after acquiring an additional 203,640 shares during the last quarter. Walleye Capital LLC boosted its stake in shares of NeuroPace by 344.6% in the 4th quarter. Walleye Capital LLC now owns 228,847 shares of the company’s stock valued at $3,533,000 after purchasing an additional 177,375 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of NeuroPace by 44.6% during the 2nd quarter. Geode Capital Management LLC now owns 485,162 shares of the company’s stock valued at $5,406,000 after purchasing an additional 149,595 shares during the last quarter. Finally, Armistice Capital LLC grew its holdings in shares of NeuroPace by 12.6% during the 3rd quarter. Armistice Capital LLC now owns 1,298,000 shares of the company’s stock valued at $13,382,000 after purchasing an additional 145,665 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.